


(S,R,S)-AHPC-phenol-C4-NH2 dihydrochloride

| | | | |
|---------------------------|---|-------|----------|
| Cat. No.: | HY-136184 | | |
| CAS No.: | 2376990-26-8 | | |
| Molecular Formula: | C ₂₈ H ₄₃ Cl ₂ N ₅ O ₅ S | | |
| Molecular Weight: | 632.64 | | |
| Target: | E3 Ligase Ligand-Linker Conjugates | | |
| Pathway: | PROTAC | | |
| Storage: | Powder | -20°C | 3 years |
| | | 4°C | 2 years |
| | In solvent | -80°C | 6 months |
| | | -20°C | 1 month |



SOLVENT & SOLUBILITY

In Vitro

DMSO : 100 mg/mL (158.07 mM; Need ultrasonic)

| Concentration | Mass | | |
|---------------|-----------|-----------|------------|
| | 1 mg | 5 mg | 10 mg |
| 1 mM | 1.5807 mL | 7.9034 mL | 15.8068 mL |
| 5 mM | 0.3161 mL | 1.5807 mL | 3.1614 mL |
| 10 mM | 0.1581 mL | 0.7903 mL | 1.5807 mL |

Please refer to the solubility information to select the appropriate solvent.

BIOLOGICAL ACTIVITY

Description

(S,R,S)-AHPC-phenol-C4-NH2 (VH032-phenol-C4-NH2) dihydrochloride is a synthesized E3 ligase ligand-linker conjugate that incorporates the (S,R,S)-AHPC based VHL ligand and a linker used in PROTAC technology^[1].

In Vitro

PROTACs contain two different ligands connected by a linker; one is a ligand for an E3 ubiquitin ligase and the other is for the target protein. PROTACs exploit the intracellular ubiquitin-proteasome system to selectively degrade target proteins^[2]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

- [1]. Scheepstra M, et al. Bivalent Ligands for Protein Degradation in Drug Discovery. *Comput Struct Biotechnol J*. 2019;17:160-176. Published 2019 Jan 25.
- [2]. [3]. Nalawansa DA, et al. PROTACs: An Emerging Therapeutic Modality in Precision Medicine. *Cell Chem Biol*. 2020;27(8):998-985.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA